Cosmos Health Secures 80,000-Unit Follow-Up Order from Pharmalink in UAE for Sky Premium Life Products

Reuters
08 May
Cosmos Health Secures 80,000-Unit Follow-Up Order from Pharmalink in UAE for Sky Premium Life Products

Cosmos Health Inc., a diversified global healthcare group, has announced a new purchase order for 80,000 units of its Sky Premium Life products from Pharmalink in the United Arab Emirates $(UAE)$. This follows the successful sell-out of an initial 130,000-unit order and aligns with the company's five-year goal of surpassing 3 million units in cumulative orders. Greg Siokas, CEO of Cosmos Health, expressed enthusiasm over the strong momentum of Sky Premium Life nutraceuticals in the UAE, crediting the effective partnership with Pharmalink for capturing significant market share in the high-growth region. Pharmalink will manage sales, marketing, regulatory affairs, logistics, and distribution for the products in the UAE.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmos Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9446595-en) on May 07, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10